World-first clinical trial targets immune molecule IL23 as potential treatment for sarcoma | Garvan Institute of Medical Research
![Patients with a rare and aggressive form of liposarcoma need treatment advances | Boehringer Ingelheim US Patients with a rare and aggressive form of liposarcoma need treatment advances | Boehringer Ingelheim US](https://www.boehringer-ingelheim.com/us/sites/default/files/2022-11/786212590_bi_sarcoma-alliance_quotegreens.jpg)
Patients with a rare and aggressive form of liposarcoma need treatment advances | Boehringer Ingelheim US
![Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges | JCO Precision Oncology Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges | JCO Precision Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/po/2022/po.2022.6/po.21.00211/20220404/images/large/po.21.00211t1.jpeg)
Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges | JCO Precision Oncology
![The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov | BMC Cancer | Full Text The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-018-5163-2/MediaObjects/12885_2018_5163_Fig2_HTML.png)
The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov | BMC Cancer | Full Text
![The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov | BMC Cancer | Full Text The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-018-5163-2/MediaObjects/12885_2018_5163_Fig1_HTML.png)
The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov | BMC Cancer | Full Text
![Published clinical trials in sarcoma and TIM histotypes. The histograms... | Download Scientific Diagram Published clinical trials in sarcoma and TIM histotypes. The histograms... | Download Scientific Diagram](https://www.researchgate.net/publication/349614101/figure/fig1/AS:998403437781002@1615049337778/Published-clinical-trials-in-sarcoma-and-TIM-histotypes-The-histograms-present-the.png)
Published clinical trials in sarcoma and TIM histotypes. The histograms... | Download Scientific Diagram
![NIH clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma | National Institutes of Health (NIH) NIH clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma | National Institutes of Health (NIH)](https://irp.nih.gov/sites/default/files/media/image/2023-02/news-12-28-2022-NIH_clinical_trial_atezolizumab_shrunk.png)
NIH clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma | National Institutes of Health (NIH)
![New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC – Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC – Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for](https://ars.els-cdn.com/content/image/1-s2.0-S0959804922004312-gr1.jpg)
New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC – Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for
![Cancers | Free Full-Text | IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers Cancers | Free Full-Text | IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers](https://www.mdpi.com/cancers/cancers-12-01768/article_deploy/html/images/cancers-12-01768-g001.png)